GSK made waves last week by pulling GLP-1 laggard Tanzeum from the market. And that move could signal weak sales ahead for other bottom-feeders in the class.
In the end, it was a tie. Sanofi and Novo Nordisk both won FDA approval for their next-gen diabetes combos Monday. Now, it's a mano-a-mano fight for share in a $6 billion market.
Novo Nordisk’s combination diabetes drug didn’t lap Sanofi’s after all. Two weeks after the FDA put off approval of the French drugmaker’s insulin-plus-GLP-1 combo, the agency has pushed back Novo’s, too.
Diabetes drugmakers are feeling the pressure from price-conscious payers and a slew of new competition. Maybe that's why DTC advertising in the category is expected to hit a high this year--and to drive overall pharma ad spending to boot.
Sanofi spent $245 million on a priority review voucher to beat Novo Nordisk to market with a diabetes med pairing a basal insulin with a GLP-1. But the FDA had other ideas.
